Elevance Health, Inc.
ELV
$397.80
-1.02%
Elevance Health, Inc. is a leading U.S. health insurer providing medical benefits to approximately 45 million members through employer, individual, and government-sponsored plans, operating within the Medical - Healthcare Plans industry. The company's distinct competitive identity is anchored by its position as the largest single provider of Blue Cross Blue Shield branded coverage, serving as the licensee in 14 states, and its expansion into pharmacy benefit management and healthcare services through strategic acquisitions. The current investor narrative is dominated by sector-wide sentiment shifts tied to regulatory updates on Medicare Advantage payments, which have recently boosted revenue visibility, alongside ongoing debates about the company's ability to navigate medical cost trends and execute on its integrated health services strategy.…
ELV
Elevance Health, Inc.
$397.80
Investment Opinion: Should I buy ELV Today?
Rating: Hold. The core thesis is that ELV is a fundamentally sound company in recovery, but investors should wait for evidence of sustained margin stabilization before committing new capital, given the extreme quarterly profitability volatility.
Supporting evidence for this cautious stance includes: 1) The stock trades at a reasonable forward P/E of 13.82x, which is near the bottom of its historical range, suggesting limited multiple compression risk. 2) Revenue continues to grow, with 9.47% YoY growth in Q4 2025, providing a top-line foundation. 3) The balance sheet is strong (D/E 0.76, Current Ratio 1.24) and generates substantial free cash flow ($3.17B TTM). 4) Major analyst firms maintain bullish ratings, and a positive sector catalyst (Medicare Advantage payments) exists. However, the severe margin compression overshadows these positives.
The two biggest risks are the continuation of margin erosion and a failure of the stock to break through technical resistance. This Hold rating would upgrade to a Buy if the company demonstrates a clear recovery in net margin back above 3% for a consecutive quarter, or if the stock experiences an unwarranted pullback towards $350 (a ~13% decline) without a deterioration in fundamentals. It would downgrade to a Sell if Q4 margin trends worsen or if revenue growth decelerates below 5% YoY. Relative to its own history, the stock appears fairly valued to slightly undervalued, but it is not compellingly cheap given the earnings uncertainty.
Sign up to view all
ELV 12-Month Price Forecast
ELV presents a classic 'show me' story. The powerful technical rebound and attractive valuation are compelling, but they are directly challenged by the alarming deterioration in quarterly profitability. The base case of range-bound trading is most likely, as the market awaits clarity on whether margins have bottomed. The stance is neutral because the risk/reward is balanced; the upside to the 52-week high (~5.7%) is modest relative to the potential downside if margins don't recover. Confidence is medium due to the high quality of contrary data points (strong cash flow vs. weak margins). The stance would upgrade to bullish on confirmation of margin stabilization for two consecutive quarters and downgrade to bearish on another quarter of sub-1.5% net margin.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Elevance Health, Inc.'s 12-month outlook, with a consensus price target around $517.14 and implied upside of +30.0% versus the current price.
Average Target
$517.14
6 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
6
covering this stock
Price Range
$318 - $517
Analyst target range
Analyst coverage is limited, with only 6 analysts providing estimates, indicating this large-cap stock may have less concentrated institutional research focus than some peers. The consensus sentiment, inferred from recent institutional actions, is bullish, with firms like Mizuho, JP Morgan, Wells Fargo, and Barclays all maintaining 'Overweight' or equivalent ratings throughout early 2026. A specific consensus price target and implied upside cannot be calculated from the provided data, which only includes EPS and revenue estimates. The wide range of revenue estimates for the upcoming period, from a low of $231.6 billion to a high of $245.8 billion, signals meaningful uncertainty among analysts regarding the company's top-line growth trajectory, which could lead to stock price volatility around earnings reports.
Bulls vs Bears: ELV Investment Factors
The investment debate for ELV centers on a powerful technical and sentiment recovery clashing with persistent fundamental concerns. The bull side currently has stronger near-term evidence, driven by a 38.56% three-month surge, a supportive regulatory catalyst, and valuation near historical lows. However, the bear case is anchored in severe and concerning quarterly margin volatility, with net margin collapsing from 4.47% to 1.10% within the year. The single most important tension is whether the recent margin compression in Q4 2025 is a temporary anomaly related to medical cost trends or investment spending, or the beginning of a sustained profitability challenge. The resolution of this issue will determine if the stock's attractive valuation is a trap or a genuine opportunity.
Bullish
- Strong Technical Momentum Reversal: The stock has surged 38.56% over the past three months, decisively breaking from its tepid 4.62% one-year gain. This powerful short-term momentum, coupled with the stock trading at 85% of its 52-week high ($426.98), signals a major shift in market sentiment and a potential new uptrend.
- Attractive Valuation Near Historical Lows: The trailing P/E of 13.73x is near the bottom of its observable historical range, which has seen multiples above 30x. This significant compression suggests the market may be pricing in excessive pessimism, presenting a potential value opportunity if fundamentals stabilize or improve.
- Solid Financial Foundation and Cash Flow: The company maintains a strong balance sheet with a manageable debt-to-equity ratio of 0.76 and robust free cash flow generation of $3.17 billion (TTM). This financial health provides stability and the capacity to fund operations, investments, and shareholder returns without excessive leverage.
- Sector-Wide Regulatory Catalyst: Recent news highlights a larger-than-expected 2027 Medicare Advantage payment increase from CMS, which has boosted revenue visibility across the managed care sector. This regulatory tailwind directly benefits Elevance's significant government-sponsored business lines.
Bearish
- Severe Quarterly Profitability Volatility: Q4 2025 net margin collapsed to 1.10%, a sharp decline from 4.47% in Q1 2025. This extreme margin compression, with net income of just $547 million on $49.75 billion in revenue, raises significant concerns about the company's ability to manage medical costs and maintain earnings stability.
- Revenue Growth Deceleration: While Q4 2025 revenue grew 9.47% YoY, this marks a slowdown from stronger growth in prior 2025 quarters. Analyst revenue estimates for the upcoming period show a wide range ($231.6B to $245.8B), reflecting uncertainty about the sustainability of the top-line trajectory.
- Valuation Gap Despite Recent Rally: Despite the 38.56% three-month surge, the stock's one-year gain of 4.62% significantly lags the S&P 500's 22.86% return, indicating a prolonged period of underperformance. The forward P/E of 13.82x is slightly higher than the trailing P/E, suggesting the market does not anticipate significant near-term earnings acceleration.
- Limited Analyst Coverage and High Short Interest: Only 6 analysts provide estimates for this large-cap stock, which may indicate less institutional research focus and could contribute to informational inefficiencies. A short ratio of 4.03 reflects a notable level of bearish sentiment among short-term traders.
ELV Technical Analysis
The stock is in a pronounced recovery phase, having surged 38.56% over the past three months, which starkly contrasts with its modest 4.62% gain over the past year, indicating a powerful short-term momentum reversal. Currently trading at $404.07, the price sits at approximately 85% of its 52-week high of $426.98, positioning it near the upper end of its annual range and suggesting strong bullish momentum, though with potential for near-term resistance. Recent momentum is exceptionally strong, with a 1-month gain of 1.11% and a 3-month surge of 38.56%, decisively breaking away from the longer-term tepid trend and signaling a potential major shift in market sentiment, supported by a beta of 0.68 indicating lower volatility than the broader market. Key technical levels are the 52-week high at $426.98 serving as immediate resistance and the 52-week low at $273.71 as major support; a breakout above resistance would confirm the new uptrend's strength, while a breakdown below the recent low of $280.74 would signal failure, with the stock's low beta of 0.68 suggesting it may exhibit less dramatic swings than the market during such tests.
Beta
0.68
0.68x market volatility
Max Drawdown
-34.1%
Largest decline past year
52-Week Range
$274-$427
Price range past year
Annual Return
+5.6%
Cumulative gain past year
| Period | ELV Return | S&P 500 |
|---|---|---|
| 1m | +1.3% | +1.5% |
| 3m | +34.9% | +13.4% |
| 6m | +15.4% | +10.9% |
| 1y | +5.6% | +24.5% |
| ytd | +12.3% | +10.0% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
ELV Fundamental Analysis
Revenue growth is positive but showed deceleration in the most recent quarter, with Q4 2025 revenue of $49.75 billion representing a 9.47% year-over-year increase, though this marks a slowdown from the stronger growth rates seen in prior quarters of 2025. Segment data reveals the Health Benefits segment, at $41.84 billion, is the primary revenue driver, while the Carelon Services segment contributed $18.66 billion, indicating a diversified model beyond pure insurance. The company is profitable but experienced significant margin compression in Q4 2025, with net income of $547 million and a net margin of just 1.10%, a sharp decline from the 4.47% net margin in Q1 2025, while the gross margin for the quarter was 23.48%. This quarterly profitability volatility, contrasted with a trailing twelve-month free cash flow of $3.17 billion, suggests underlying earnings power is being impacted by near-term factors like medical cost trends or investment spending. The balance sheet is solid with a manageable debt level, evidenced by a debt-to-equity ratio of 0.76 and a current ratio of 1.24, indicating sufficient short-term liquidity. Strong free cash flow generation of $3.17 billion (TTM) and a return on equity of 12.90% demonstrate the company's ability to fund operations and provide shareholder returns without excessive reliance on external financing, supporting its financial health.
Quarterly Revenue
$49.7B
2025-12
Revenue YoY Growth
+0.09%
YoY Comparison
Gross Margin
+0.23%
Latest Quarter
Free Cash Flow
$3.2B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is ELV Overvalued?
Given a positive net income, the primary valuation metric is the Price-to-Earnings (PE) ratio. The trailing PE is 13.73x, while the forward PE is slightly higher at 13.82x; the minimal gap suggests the market expects largely stable, rather than accelerating, earnings growth in the near term. Compared to sector averages (data not available in the provided set), a precise premium/discount calculation cannot be made, but a PE in the low-teens is generally considered reasonable for a large, mature managed care company, potentially indicating a discount if sector averages are higher. Historically, the stock's own valuation has compressed significantly; its current trailing PE of 13.73x is near the bottom of its observable range over recent years, which has seen PEs above 30x, suggesting the market may be pricing in a more pessimistic outlook or reflecting the recent margin pressure, presenting a potential value opportunity if fundamentals stabilize.
PE
13.7x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 11x~50x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
10.5x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks are primarily centered on extreme earnings volatility and margin pressure. The Q4 2025 net margin of 1.10% represents a dramatic 75% decline from the Q1 2025 level of 4.47%, indicating the company's profitability is highly sensitive to quarterly medical cost fluctuations or investment cycles. While the balance sheet is solid with a debt-to-equity of 0.76 and strong TTM FCF of $3.17B, this earnings instability makes forecasting difficult and could lead to significant earnings misses. Revenue concentration in the Health Benefits segment ($41.84B in Q4) also creates dependence on the competitive and regulated U.S. health insurance market.
Market & Competitive Risks include valuation compression risk if the recent rally falters. The stock's low beta of 0.68 suggests it is less volatile than the market, but its significant underperformance vs. the S&P 500 over one year (-18.24% relative strength) shows it has been out of favor. The primary external threat is regulatory changes impacting Medicare Advantage and Medicaid reimbursement rates, though recent news on payment increases is a positive. Competitive pressure from peers like UnitedHealth and CVS in integrating insurance and healthcare services could pressure margins further. The stock's low P/E multiple may reflect a sector-wide de-rating rather than a company-specific discount.
Worst-Case Scenario involves a failure to arrest the margin decline, leading to consecutive earnings disappointments. This could trigger analyst downgrades, a loss of investor confidence in the integrated services strategy, and a re-test of the recent lows. The specific chain would be: Q4 margin weakness persists into 2026 -> management guidance is cut -> institutional selling accelerates -> the stock breaks below key support. The realistic downside is a return to the 52-week low of $273.71, which represents a potential loss of approximately -32% from the current price of $404.07. The March 2026 low of $280.74 provides a nearer-term support level for a -30% decline.
FAQ
The key risks, ranked by severity, are: 1) Profitability/Earnings Risk: Extreme quarterly margin volatility, evidenced by the Q4 2025 net margin collapse to 1.10%, poses the greatest threat to the investment thesis. 2) Regulatory Risk: The company's heavy exposure to government-sponsored plans (Medicare/Medicaid) makes it sensitive to changes in reimbursement rates, though recent news has been positive. 3) Competitive/Market Risk: Intense competition in integrated health services could pressure margins further, and the stock's low beta of 0.68 hasn't prevented it from significantly underperforming the S&P 500 over the past year. 4) Sentiment/Technical Risk: The stock recently hit a -34.09% drawdown and faces resistance at its 52-week high; failure to break through could lead to another period of stagnation.
The 12-month forecast presents three scenarios with associated probabilities. The Base Case (55% probability) sees the stock trading between $380 and $427, as margins stabilize and the stock oscillates near its 52-week high. The Bull Case (30% probability), targeting $427 to $460, requires a clear margin recovery and successful execution of the services strategy. The Bear Case (15% probability) warns of a drop back towards the $274-$320 range if margin weakness persists. The Base Case is most likely, anchored by the assumption that net margin stabilizes between 1.5% and 2.5%. The key to the forecast is the next quarter's profitability data, which will determine the trajectory.
ELV appears fairly valued to slightly undervalued relative to its own history, but the valuation adequately reflects current risks. The trailing P/E of 13.73x is near the bottom of its observable historical range, which has seen multiples above 30x, suggesting a significant discount. However, this compressed multiple likely prices in the recent profitability challenges. Compared to sector peers, a precise premium/discount cannot be calculated, but a low-teens P/E is typical for mature managed care companies. The market is paying a fair price for a company with stable revenue growth (~9.5% in Q4) but highly volatile earnings, implying low expectations for near-term earnings acceleration.
ELV is a conditional buy, suitable for value-oriented investors with a medium-term horizon who can tolerate uncertainty. The stock offers an attractive valuation (P/E 13.73x near historical lows) and a solid 1.97% dividend, supported by strong free cash flow. However, it is not a good buy for those seeking stability, as severe quarterly margin volatility (net margin fell from 4.47% to 1.10% in 2025) presents significant risk. The recent 38.56% three-month rally also reduces the near-term margin of safety. It is a good buy for investors who believe the margin compression is temporary and are willing to wait for a confirmed recovery, potentially on any pullback towards the $370-$380 range.
ELV is more suitable for a long-term investment horizon of 2-3 years rather than short-term trading. As a large, mature company in a regulated industry, its value proposition is based on financial stability, cash flow generation, and a potential valuation recovery—theses that take time to play out. The low beta of 0.68 and modest dividend yield support a buy-and-hold approach. However, short-term traders face headwinds from high short interest (ratio 4.03) and potential volatility around quarterly earnings due to margin uncertainty. Given the need to confirm a turnaround in profitability, a minimum holding period of 12-18 months is suggested to allow the fundamental story to develop.
